People without diabetes can lose up to 13% of their starting weight in 6 months using tirzepatide (Mounjaro) as an off-label ...

Irish government mounts a St. Patrick’s Day diplomatic offensive to try and calm Trump anger at ‘massive’ trade surplus.

Roche moved to enter the booming weight-loss drug market now dominated by Novo Nordisk and Eli Lilly. The Swiss ...

A new study found that fair prices for medications like Wegovy and Zepbound would be hundreds less per month than they are ...

Eli Lilly (LLY) believes its experimental weight-loss pill could make GLP-1 treatments more accessible worldwide.

With official shortages ended, but the first generics gearing up for launch, companies are looking for the next generation of ...

Novo and Lilly’s campaigns are not limited to advertisements alone, and both companies are trying to raise awareness around obesity through research studies and conferences.

Like many pharma stocks, Eli Lilly (NYSE: LLY) offers investors a bit of safety -- and it's an element you can count on ...

FDA is aware that some patients and health care professionals may look to unapproved versions of GLP-1 – glucagon-like peptide-1 receptor agonists – drugs, including semaglutide and tirzepatide, as an ...

An Eli Lilly exec said the company’s experimental weight-loss pill could make GLP-1 treatments more accessible worldwide, as ...

Eli Lilly & Co. said Tuesday it’s cutting ... after a regulatory ruling that there’s no longer a shortage of weight-loss drugs that had allowed for alternatives to be made, sending the stock ...

Woman says she got less expensive drug for weight loss after being denied by insurance Both Eli Lilly and Novo Nordisk now ...